title: Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice.
abstract: A subset of patients with Parkinson's disease acquires a debilitating dementia characterized by severe cognitive impairments (i.e. Parkinson's disease dementia; PDD). Brains from PDD patients show extensive cholinergic loss as well as dopamine (DA) depletion. We used a mutant mouse model to directly test whether combined cholinergic and DA depletion leads to a cognitive profile resembling PDD. Mice carrying heterozygous deletion of the high-affinity, hemicholinium-3-sensitive choline transporter (CHT(HET)) show reduced levels of acetylcholine throughout the brain. We achieved bilateral DA depletion in CHT(HET) and wild-type (WT) littermates via intra-striatal infusion of 6-hydroxydopamine (6-OHDA), or used vehicle as control. Executive function and memory were evaluated using rodent versions of cognitive tasks commonly used with human subjects: the set-shifting task and spatial and novel-object recognition paradigms. Our studies revealed impaired acquisition of attentional set in the set-shifting paradigm in WT-6OHDA and CHT(HET)-vehicle mice that was exacerbated in the CHT(HET)-6OHDA mice. The object recognition test following a 24-hour delay was also impaired in CHT(HET)-6OHDA mice compared with all other groups. Treatment with acetylcholinesterase (AChE) inhibitors physostigmine (0.05 or 0.1 mg/kg) and donepezil (0.1 and 0.3 mg/kg) reversed the impaired object recognition of the CHT(HET)-6OHDA mice. Our data demonstrate an exacerbated cognitive phenotype with dual ACh and DA depletion as compared with either insult alone, with traits analogous to those observed in PDD patients. The results suggest that combined loss of DA and ACh could be sufficient for pathogenesis of specific cognitive deficits in PDD.
authors.affiliation: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
authors.forename: Lilia
authors.initials: L
authors.lastname: Zurkovsky
authors.forename: Evgeny
authors.initials: E
authors.lastname: Bychkov
authors.forename: Elviche L
authors.initials: EL
authors.lastname: Tsakem
authors.forename: Carley
authors.initials: C
authors.lastname: Siedlecki
authors.forename: Randy D
authors.initials: RD
authors.lastname: Blakely
authors.forename: Eugenia V
authors.initials: EV
authors.lastname: Gurevich
mesh_terms: D000109:Acetylcholine / Q000172:deficiency / Q000502:physiology*; D000818:Animals; D018678:Cholinergic Agents / Q000494:pharmacology; D003072:Cognition Disorders / Q000209:etiology* / Q000503:physiopathology* / Q000523:psychology; D003704:Dementia / Q000209:etiology / Q000503:physiopathology / Q000523:psychology; D004195:Disease Models, Animal; D004298:Dopamine / Q000172:deficiency* / Q000502:physiology; D006426:Hemicholinium 3 / Q000494:pharmacology; D006801:Humans; D008297:Male; D026901:Membrane Transport Proteins / Q000172:deficiency / Q000235:genetics; D008568:Memory / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D020734:Parkinsonian Disorders / Q000150:complications* / Q000503:physiopathology / Q000523:psychology*; D015398:Signal Transduction
chemical_list: D018678:Cholinergic Agents; D026901:Membrane Transport Proteins; C065637:choline transporter; D006426:Hemicholinium 3; D000109:Acetylcholine; D004298:Dopamine